Company news
Artelo Biosciences, Inc. news in 2026
Artelo Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.
Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
October 29, 2026
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
October 26, 2026
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
October 7, 2026
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
September 23, 2026
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
September 16, 2026
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
August 17, 2026
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
August 13, 2026
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
July 22, 2026
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
July 16, 2026
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
July 14, 2026
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
July 13, 2026
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026
June 29, 2026
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
June 10, 2026
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
May 14, 2026
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development
April 28, 2026
Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile
April 20, 2026
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements
April 7, 2026
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
March 29, 2026
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
March 26, 2026
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
March 24, 2026
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients
March 17, 2026
Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results
February 24, 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 25 slides · September 2026